Last update Dec. 10, 2022
It is an antimuscarinic/anticholinergic with peripheral effects similar to those of atropine. It has antispasmodic and antiemetic properties and has been used in irritable bowel syndrome. Oral, subcutaneous, intramuscular or intravenous administration 2 to 4 times a day.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (large volume of distribution, short half-life, and low oral bioavailability) make it unlikely that it will pass into breast milk in clinically significant amounts.
Intestinal absorption is practically non-existent (Noguchi 1983), so the little that may pass into breast milk will not be absorbed by the infant.
Although antimuscarinics can decrease prolactin production (Müller 1983, Masala 1982), once lactation is established, milk production depends more on the repeated stimulation of suckling than on prolactin levels.
The literature on this drug is scarce and it is sold in few countries.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM